The COVID-19 pandemic highlighted the urgent need for effective therapeutic agents against SARS-CoV-2. Although vaccines ...

Small-molecule inhibitors targeting viral proteins could serve as an effective alternative for controlling the spread of COVID-19 at both individual and community levels. In this vein, a recent study ...

Elevated levels of NE, proteinase 3 (PR3), and cathepsin G (CatG) can overwhelm the natural inhibitors, altering the airway microenvironment and increasing the risk of infection. Neutrophils play ...

In this Review, we highlight recent developments in this area and emphasize the importance of studying the role of endolysosomal proteases, and their natural inhibitors, in the initiation and ...

Announcing a new publication for Acta Materia Medica journal. Phosphodiesterase-4 (PDE4), a member of the phosphodiesterase ...

The Lancet Respiratory Medicine (JCR Q1, IF: 38.7), the leading journal in the fields of respiratory and critical care medicine, published a phase 2 clinical study article on China's first DPP-1 ...

Enodia Therapeutics stems from pioneering research at the Institut Pasteur, with the discovery of the mechanism of action of Mycolactone, a natural Sec61 inhibitor responsible for Buruli Ulcers.